Short leukocyte telomeres predict 25-year Alzheimer's disease incidence in non-APOE ε4-carriers.
Fernanda Schäfer HackenhaarMaria JosefssonAnnelie Nordin AdolfssonMattias LandforsKarolina KauppiMagnus HultdinRolf AdolfssonSofie DegermanSara PudasPublished in: Alzheimer's research & therapy (2021)
Our findings from two complementary competing risk time-to-event models indicate that short rLTL may be a valuable predictor of the AD incidence in non-APOE ε4-carriers, on average 8 years before AD onset. More generally, the findings highlight the importance of accounting for competing risks, as well as the APOE status of participants in AD biomarker research.